Cristina Eguren, Ariadna Navarro-Blasco, Marina Corral-Forteza, Alejandra Reolid-Pérez, Núria Setó-Torrent, Alejandro García-Navarro, David Prieto-Merino, Eva Núñez-Delegido, Pedro Sánchez-Pellicer, Vicente Navarro-López
{"title":"评估口服益生菌对痤疮疗效的随机临床试验。","authors":"Cristina Eguren, Ariadna Navarro-Blasco, Marina Corral-Forteza, Alejandra Reolid-Pérez, Núria Setó-Torrent, Alejandro García-Navarro, David Prieto-Merino, Eva Núñez-Delegido, Pedro Sánchez-Pellicer, Vicente Navarro-López","doi":"10.2340/actadv.v104.33206","DOIUrl":null,"url":null,"abstract":"<p><p>The relevance of the gut microbiota in some skin inflammatory diseases, including acne vulgaris, has been emphasized. Probiotics could play a role in the modulation of the microbiota, improving the clinical course of this disease. A 12-week randomized, double-blind, placebo-controlled, clinical trial with patients aged 12 to 30 years with acne vulgaris was conducted. The study product was a capsule composed of the probiotic Lacticaseibacillus rhamnosus (CECT 30031) and the cyanobacterium Arthrospira platensis (BEA_IDA_0074B). Patients with improvement in the Acne Global Severity Scale were 10/34 (29.41%) in the placebo group compared with 20/40 (50%) in the probiotic group (p = 0.03). A significant reduction (p = 0.03) in the number of non-inflammatory acne lesions was observed in the probiotic group (-18.60 [-24.38 to -12.82]) vs the placebo group (-10.54 [-17.43 to -3.66]). Regarding the number of total lesions, a reduction almost reaching statistical significance (p = 0.06) was observed in the probiotic group (-27.94 [-36.35 to -19.53]) compared with the placebo group (-18.31 [-28.21 to -8.41]). In addition, patients with improvement attending the Global Acne Grading System were 7/34 (20.58%) in the placebo group vs 17/40 (42.50%) in the probiotic group (p = 0.02). The number of adverse events was similar in both groups. The probiotic used in this study was effective and well tolerated, and it should be considered for acne vulgaris patients.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"104 ","pages":"adv33206"},"PeriodicalIF":3.5000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110809/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris.\",\"authors\":\"Cristina Eguren, Ariadna Navarro-Blasco, Marina Corral-Forteza, Alejandra Reolid-Pérez, Núria Setó-Torrent, Alejandro García-Navarro, David Prieto-Merino, Eva Núñez-Delegido, Pedro Sánchez-Pellicer, Vicente Navarro-López\",\"doi\":\"10.2340/actadv.v104.33206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The relevance of the gut microbiota in some skin inflammatory diseases, including acne vulgaris, has been emphasized. Probiotics could play a role in the modulation of the microbiota, improving the clinical course of this disease. A 12-week randomized, double-blind, placebo-controlled, clinical trial with patients aged 12 to 30 years with acne vulgaris was conducted. The study product was a capsule composed of the probiotic Lacticaseibacillus rhamnosus (CECT 30031) and the cyanobacterium Arthrospira platensis (BEA_IDA_0074B). Patients with improvement in the Acne Global Severity Scale were 10/34 (29.41%) in the placebo group compared with 20/40 (50%) in the probiotic group (p = 0.03). A significant reduction (p = 0.03) in the number of non-inflammatory acne lesions was observed in the probiotic group (-18.60 [-24.38 to -12.82]) vs the placebo group (-10.54 [-17.43 to -3.66]). Regarding the number of total lesions, a reduction almost reaching statistical significance (p = 0.06) was observed in the probiotic group (-27.94 [-36.35 to -19.53]) compared with the placebo group (-18.31 [-28.21 to -8.41]). In addition, patients with improvement attending the Global Acne Grading System were 7/34 (20.58%) in the placebo group vs 17/40 (42.50%) in the probiotic group (p = 0.02). The number of adverse events was similar in both groups. The probiotic used in this study was effective and well tolerated, and it should be considered for acne vulgaris patients.</p>\",\"PeriodicalId\":6944,\"journal\":{\"name\":\"Acta dermato-venereologica\",\"volume\":\"104 \",\"pages\":\"adv33206\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110809/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta dermato-venereologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2340/actadv.v104.33206\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta dermato-venereologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/actadv.v104.33206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
肠道微生物群与一些皮肤炎症疾病(包括寻常痤疮)的相关性已得到强调。益生菌可在调节微生物群方面发挥作用,从而改善这种疾病的临床病程。我们对 12 至 30 岁的寻常型痤疮患者进行了为期 12 周的随机、双盲、安慰剂对照临床试验。研究产品是一种由益生菌鼠李糖乳杆菌(CECT 30031)和蓝藻节杆菌(BEA_IDA_0074B)组成的胶囊。痤疮总体严重程度量表(Acne Global Severity Scale)有所改善的患者在安慰剂组为 10/34(29.41%),而在益生菌组为 20/40(50%)(p = 0.03)。益生菌组(-18.60 [-24.38 to -12.82])与安慰剂组(-10.54 [-17.43 to -3.66])相比,非炎症性痤疮皮损数量明显减少(p = 0.03)。在病变总数方面,益生菌组(-27.94 [-36.35 to -19.53])与安慰剂组(-18.31 [-28.21 to -8.41])相比,几乎达到统计学意义(p = 0.06)。此外,在全球痤疮分级系统(Global Acne Grading System)中,安慰剂组的改善率为 7/34(20.58%),而益生菌组为 17/40(42.50%)(P = 0.02)。两组的不良反应数量相似。本研究中使用的益生菌有效且耐受性良好,寻常型痤疮患者应考虑使用。
A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris.
The relevance of the gut microbiota in some skin inflammatory diseases, including acne vulgaris, has been emphasized. Probiotics could play a role in the modulation of the microbiota, improving the clinical course of this disease. A 12-week randomized, double-blind, placebo-controlled, clinical trial with patients aged 12 to 30 years with acne vulgaris was conducted. The study product was a capsule composed of the probiotic Lacticaseibacillus rhamnosus (CECT 30031) and the cyanobacterium Arthrospira platensis (BEA_IDA_0074B). Patients with improvement in the Acne Global Severity Scale were 10/34 (29.41%) in the placebo group compared with 20/40 (50%) in the probiotic group (p = 0.03). A significant reduction (p = 0.03) in the number of non-inflammatory acne lesions was observed in the probiotic group (-18.60 [-24.38 to -12.82]) vs the placebo group (-10.54 [-17.43 to -3.66]). Regarding the number of total lesions, a reduction almost reaching statistical significance (p = 0.06) was observed in the probiotic group (-27.94 [-36.35 to -19.53]) compared with the placebo group (-18.31 [-28.21 to -8.41]). In addition, patients with improvement attending the Global Acne Grading System were 7/34 (20.58%) in the placebo group vs 17/40 (42.50%) in the probiotic group (p = 0.02). The number of adverse events was similar in both groups. The probiotic used in this study was effective and well tolerated, and it should be considered for acne vulgaris patients.
期刊介绍:
Acta Dermato-Venereologica publishes high-quality manuscripts in English in the field of Dermatology and Venereology, dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of Review articles in special areas, as well as short Letters to the Editor to stimulate debate and to disseminate important clinical observations. Acta Dermato-Venereologica has rapid publication times and is amply illustrated with a large number of colour photographs.